P782: A PHASE 2, RANDOMIZED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

• Jun-Ho Jang,
• Raymond Wong,
• Rodrigo Pavani,
• Lisa Aurand,
• Quang P. Nguyen,
• Lorah Perlee,
• Amal Souttou,
• Jonathan Weyne,
• Richard Kelly

Affiliations

Jun-Ho Jang

1 Samsung Medical Center, Seoul, Korea, Rep. of South

Raymond Wong

2 Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong

Rodrigo Pavani

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Lisa Aurand

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Quang P. Nguyen

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Lorah Perlee

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Amal Souttou

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Jonathan Weyne

3 Regeneron Pharmaceuticals, Inc., Tarrytown, United States

Richard Kelly

4 St James’s University Hospital, Leeds, United Kingdom